An oral pill nearly doubled survival for patients with advanced pancreatic cancer in a phase 3 trial

An experimental once-daily pill roughly doubled how long patients with previously treated advanced pancreatic cancer lived in a large phase 3 trial, a rare and striking result in a disease that has resisted decades of progress. The drug, daraxonrasib, works by shutting down a mutated cancer-driving protein that had long been considered nearly impossible to target with a pill.

Pancreatic cancer is among the deadliest common cancers, and patients whose disease has spread and progressed after initial chemotherapy have had few options and grim odds. That is the context that made the trial data stand out when they were presented to oncologists this year, drawing attention as one of the more consequential findings in the field.

What the RASolute 302 trial measured

The study, called RASolute 302, tested daraxonrasib against standard chemotherapy in people whose metastatic pancreatic cancer had already been treated. As reported from the trial, patients on the pill had a median overall survival of 13.2 months compared with 6.7 months for those on chemotherapy, a hazard ratio of 0.40. In plain terms, the median patient on the drug lived close to twice as long as the median patient on chemotherapy, and the drug also slowed the time before the cancer resumed growing.

The trial randomized roughly 500 patients, split between the once-daily oral drug and an investigator’s choice of standard chemotherapy regimens. Median overall survival is the point at which half of patients in a group have died, so a jump from 6.7 to 13.2 months describes a shift in the middle of the curve rather than a cure — a meaningful extension of life for a population that has historically been measured in months, not years.

How a RAS(ON) inhibitor attacks the tumor

The drug belongs to a class aimed at RAS, a family of proteins that act as on-off switches for cell growth and that are mutated in the large majority of pancreatic tumors. For most of the history of cancer research, RAS was labeled “undruggable” because its shape offered no obvious pocket for a small molecule to grab. Daraxonrasib is described as a multi-selective RAS inhibitor that targets the active, growth-signaling form of the protein, an approach that the American Society of Clinical Oncology highlighted as nearly doubling survival time in patients with metastatic pancreatic cancer.

Because pancreatic cancer is so heavily driven by RAS mutations, a drug that can switch that protein off strikes at a central engine of the disease rather than a peripheral feature. That mechanism is why researchers see the result as potentially generalizable: if blocking active RAS extends survival here, it points to a strategy that could matter across the many cancers where the same protein is mutated.

Where the drug stands in the approval process

The results do not yet mean the pill is available to patients outside a trial. The findings were presented as late-breaking data at a major oncology meeting and published in a leading medical journal, and the drug has drawn regulatory interest, but it has not received full marketing approval. Reporting from an academic cancer center noted that daraxonrasib has been granted a Breakthrough Therapy designation, a status the Food and Drug Administration uses to speed the review of promising treatments.

A Breakthrough designation accelerates the regulatory process but is not the same as an approval; the agency still has to review the full data package before the drug could be prescribed broadly. The distinction matters for patients and their families, because trial results — however strong — describe what happened in a controlled study population rather than a treatment currently in pharmacies. The trial safety profile was described as generally manageable, with a low rate of patients stopping treatment because of side effects, an important consideration for a daily pill.

Why the result carries weight in a stubborn disease

The significance is best understood against how little the standard outlook for advanced pancreatic cancer has moved. Survival gains in the disease have typically been measured in weeks, and many promising candidates have failed in late-stage testing. A phase 3 trial that shows the median patient living several months longer, achieved with an oral drug rather than infused chemotherapy, is the kind of margin that changes how researchers talk about what is possible.

Caution remains warranted. Median survival still landed a little over a year, the disease continued to progress in most patients, and long-term outcomes and real-world performance will take time to establish. Experts also note that a single trial, even a strong one, needs to be weighed alongside the full published data and eventual regulatory review before it reshapes standard care.

Even with those caveats, the RASolute 302 data represent a genuine step in a disease long defined by its resistance to treatment. A pill that targets a protein once written off as unreachable, and that nearly doubles median survival in patients who had already exhausted first-line options, gives oncologists something the field has rarely had here — a clear, phase 3-backed signal that a hard biological problem may finally be yielding.

This article was researched and written with the assistance of AI and reviewed by an editor prior to publication.

More from Morning Overview